The “need for speed” that drove pharmaceutical developers during the pandemic is no longer a one-off phenomenon; it is increasingly becoming business as usual. This shift is reflected in the industry’s demand for accelerated processes for chemistry, manufacturing, and controls (CMC) development. Given the risks implied by this market-driven acceleration, potential partnerships with contract development and manufacturing organizations (CDMOs) must be thoroughly vetted.
Related Resources
All Resources
post
Oral Drug Product Development of Small Molecules
Read More
white-paper
The New Chemistry, Manufacturing, and Controls (CMC) Regulations in China
Read More
post
Why FDA PreCheck is a game-changer for small & mid-sized pharma — and how these companies should lean in
Read More
white-paper
Solid-Phase Oligonucleotide Synthesis (SPOS) and Liquid-Phase Oligonucleotide Synthesis (LPOS): Complementary or Competitive Processes?
Read More
Let's move from science to success.
Let’s Talk